8:05 AM
 | 
Jun 29, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Galapagos reports CF data, provides update on AbbVie partnership

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported that GLPG2737 failed to significantly improve lung function in the Phase II PELICAN trial to treat cystic fibrosis. The company also said partner AbbVie Inc. (NYSE:ABBV) has scrapped plans for a second trial of a triple combination CF therapy.

The double-blind, German PELICAN trial enrolled 22 CF patients homozygous for the F508del mutation who were on stable treatment with Orkambi ivacaftor/lumacaftor from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) for at least 12 weeks prior to receiving GLPG2737. Patients were required to continue treatment with Orkambi for...

Read the full 424 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >